Skip to main content

. 1983 Aug;48(2):315–317. doi: 10.1038/bjc.1983.188

Adriamycin cardiotoxicity monitoring by radionuclide scan.

B A Robinson, B M Colls, J G Turner

PMCID: PMC2011444 PMID: 6882671

315

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Alexander J., Dainiak N., Berger H. J., Goldman L., Johnstone D., Reduto L., Duffy T., Schwartz P., Gottschalk A., Zaret B. L. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979 Feb 8;300(6):278–283. doi: 10.1056/NEJM197902083000603. [DOI] [PubMed] [Google Scholar]
Billingham M. E., Mason J. W., Bristow M. R., Daniels J. R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978 Jun;62(6):865–872. [PubMed] [Google Scholar]
Bristow M. R., Lopez M. B., Mason J. W., Billingham M. E., Winchester M. A. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer. 1982 Jul 1;50(1):32–41. doi: 10.1002/1097-0142(19820701)50:1<32::aid-cncr2820500108>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
Ritchie J. L., Singer J. W., Thorning D., Sorensen S. G., Hamilton G. W. Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer. 1980 Sep 1;46(5):1109–1116. doi: 10.1002/1097-0142(19800901)46:5<1109::aid-cncr2820460506>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
Von Hoff D. D., Layard M. W., Basa P., Davis H. L., Jr, Von Hoff A. L., Rozencweig M., Muggia F. M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–717. doi: 10.7326/0003-4819-91-5-710. [DOI] [PubMed] [Google Scholar]
Young R. C., Ozols R. F., Myers C. E. The anthracycline antineoplastic drugs. N Engl J Med. 1981 Jul 16;305(3):139–153. doi: 10.1056/NEJM198107163050305. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES